Cargando…
Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients
The association between interleukin (IL)-6 promoter polymorphism (-174 G/C), circulating IL-6 levels and mortality in septic patients has scarcely been addressed, and then only in studies of small sample size, and a direct association among them has not been previously reported. Therefore, the purpo...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133861/ https://www.ncbi.nlm.nih.gov/pubmed/27834822 http://dx.doi.org/10.3390/ijms17111861 |
_version_ | 1782471355167408128 |
---|---|
author | Lorente, Leonardo Martín, María M. Pérez-Cejas, Antonia Barrios, Ysamar Solé-Violán, Jordi Ferreres, José Labarta, Lorenzo Díaz, César Jiménez, Alejandro |
author_facet | Lorente, Leonardo Martín, María M. Pérez-Cejas, Antonia Barrios, Ysamar Solé-Violán, Jordi Ferreres, José Labarta, Lorenzo Díaz, César Jiménez, Alejandro |
author_sort | Lorente, Leonardo |
collection | PubMed |
description | The association between interleukin (IL)-6 promoter polymorphism (-174 G/C), circulating IL-6 levels and mortality in septic patients has scarcely been addressed, and then only in studies of small sample size, and a direct association among them has not been previously reported. Therefore, the purpose of our study was to determine whether this association exists. An observational, prospective and multicenter study including severe septic patients was undertaken and serum IL-6 levels at severe sepsis diagnosis and IL-6 promoter polymorphism (-174 G/C) were determined. The end-point of the study was 30-day mortality. The study included 263 patients with the following genotypes of IL-6 promoter polymorphism (-174 G/C): 123 (46.8%) GG, 110 (41.8%) GC and 30 (11.4%) CC. CC homozygous patients showed lower sepsis-related organ failure assessment (SOFA) score, serum IL-6 levels and mortality at 30 days compared to those with other genotypes (GC or GG). On regression analysis, CC homozygous patients showed lower 30-day mortality than those with genotype GG (odds ratio = 0.21; 95% CI = 0.053−0.838; p = 0.03) or GC (hazard ratio = 0.28; 95% CI = 0.074−1.037; p = 0.06). The most important results of our study were that CC might be a favorable genotype in septic patients showing lower serum IL-6 levels and lower risk of death within 30 days. |
format | Online Article Text |
id | pubmed-5133861 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-51338612016-12-12 Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients Lorente, Leonardo Martín, María M. Pérez-Cejas, Antonia Barrios, Ysamar Solé-Violán, Jordi Ferreres, José Labarta, Lorenzo Díaz, César Jiménez, Alejandro Int J Mol Sci Article The association between interleukin (IL)-6 promoter polymorphism (-174 G/C), circulating IL-6 levels and mortality in septic patients has scarcely been addressed, and then only in studies of small sample size, and a direct association among them has not been previously reported. Therefore, the purpose of our study was to determine whether this association exists. An observational, prospective and multicenter study including severe septic patients was undertaken and serum IL-6 levels at severe sepsis diagnosis and IL-6 promoter polymorphism (-174 G/C) were determined. The end-point of the study was 30-day mortality. The study included 263 patients with the following genotypes of IL-6 promoter polymorphism (-174 G/C): 123 (46.8%) GG, 110 (41.8%) GC and 30 (11.4%) CC. CC homozygous patients showed lower sepsis-related organ failure assessment (SOFA) score, serum IL-6 levels and mortality at 30 days compared to those with other genotypes (GC or GG). On regression analysis, CC homozygous patients showed lower 30-day mortality than those with genotype GG (odds ratio = 0.21; 95% CI = 0.053−0.838; p = 0.03) or GC (hazard ratio = 0.28; 95% CI = 0.074−1.037; p = 0.06). The most important results of our study were that CC might be a favorable genotype in septic patients showing lower serum IL-6 levels and lower risk of death within 30 days. MDPI 2016-11-08 /pmc/articles/PMC5133861/ /pubmed/27834822 http://dx.doi.org/10.3390/ijms17111861 Text en © 2016 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC-BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Lorente, Leonardo Martín, María M. Pérez-Cejas, Antonia Barrios, Ysamar Solé-Violán, Jordi Ferreres, José Labarta, Lorenzo Díaz, César Jiménez, Alejandro Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients |
title | Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients |
title_full | Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients |
title_fullStr | Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients |
title_full_unstemmed | Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients |
title_short | Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients |
title_sort | association between interleukin-6 promoter polymorphism (-174 g/c), serum interleukin-6 levels and mortality in severe septic patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133861/ https://www.ncbi.nlm.nih.gov/pubmed/27834822 http://dx.doi.org/10.3390/ijms17111861 |
work_keys_str_mv | AT lorenteleonardo associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients AT martinmariam associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients AT perezcejasantonia associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients AT barriosysamar associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients AT soleviolanjordi associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients AT ferreresjose associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients AT labartalorenzo associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients AT diazcesar associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients AT jimenezalejandro associationbetweeninterleukin6promoterpolymorphism174gcseruminterleukin6levelsandmortalityinseveresepticpatients |